Evaluation of targeted drugs in combination with the MDM2 antagonist RG7388 in neuroblastoma Ghent University
Background: Neuroblastoma is the second most common solid malignant tumor in children and accounts for approximately 15% of all pediatric cancer-related deaths. As in most pediatric cancers, TP53 mutations are relatively rare in neuroblastoma and the p53 tumor suppressor protein is mainly kept inactive by aberrations in the p14ARF/MDM2/TP53 axis resulting in increased activity of MDM2. These biological conditions make neuroblastoma specifically ...